Your browser doesn't support javascript.
loading
MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment.
Bartko, Ewa A; Mellergaard, Maiken; Groen, Solveig S; Nielsen, Signe Holm; Elberling, Jesper; Handberg, Aase; Poulsen, Lars K; Blom, Lars H; Jensen, Bettina M.
Afiliação
  • Bartko EA; Allergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark.
  • Mellergaard M; Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
  • Groen SS; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Nielsen SH; ImmunoScience, Nordic Bioscience, Herlev, Denmark.
  • Elberling J; Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Handberg A; ImmunoScience, Nordic Bioscience, Herlev, Denmark.
  • Poulsen LK; Allergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark.
  • Blom LH; Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.
  • Jensen BM; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Allergy ; 79(9): 2558-2561, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38953463

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antialérgicos / Metaloproteinase 9 da Matriz / Omalizumab / Urticária Crônica Limite: Female / Humans / Male Idioma: En Revista: Allergy Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antialérgicos / Metaloproteinase 9 da Matriz / Omalizumab / Urticária Crônica Limite: Female / Humans / Male Idioma: En Revista: Allergy Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Dinamarca
...